Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

Also called NCT02217501

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 159 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02217501
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02217501. Randomized; no masking; primary purpose treatment. Start 2015-11 (registry gives no type); primary completion 2020-01-30 (actual). Results posted on 2021-02-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
Acronym
ASPIRE
Condition
Peripheral Arterial Disease
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Acetylsalicylic acid (ASA)
Lead sponsor
University of Texas Southwestern Medical Center (class: other)

Record details

Record id
cardio:ct-nct02217501
Content hash
185eddab7fe2e5af4619523155dfa9b77e44e5099c1971ead69c1a5b51d1432f